News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

03 October 2016 Therapeutic Goods Administration Approves IDELVION® - CSL Behring’s Novel Recombinant Haemophilia B Treatment with up to 14-day Dosing Intervals

CSL Behring announced that the Australian Therapeutic Goods Administration (TGA) has approved IDELVION®[albutrepenonacog alfa] in patients with haemophilia B (congenital factor IX deficiency).

> Read More
29 September 2016 Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves CSL Behring’s IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals

Global biotherapeutics leader CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IDELVION® [Albutrepenonacog Alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the prevention of bleeding tendency in patients with factor IX deficiency.

> Read More
21 September 2016 CSL Behring Reinforces Global Leadership at the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID)

CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona.

> Read More
16 September 2016 General Counsel Greg Boss of Global Biotherapeutics Leader CSL Limited Receives Career Honor from Directors Roundtable

General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in recognition of his professional accomplishments and passion for ethical leadership.

> Read More
06 September 2016 CSL Behring Provides Leadership at Global Congress

CSL Behring is hosting an Expert Forum "Modifying Alpha-1 Antitrypsin Deficiency Related Emphysema" today during the 26th International Congress of the European Respiratory Society (ERS) in London.

> Read More
Page 6 of 7 First | Previous | Last

LinkedIn Twitter Facebook Google+